Tributary Capital Management LLC Sells 1,423 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Tributary Capital Management LLC trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 344,838 shares of the specialty pharmaceutical company’s stock after selling 1,423 shares during the quarter. Tributary Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $11,762,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Quadrant Capital Group LLC grew its stake in Supernus Pharmaceuticals by 1,117.6% during the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,330 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Supernus Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,314 shares of the specialty pharmaceutical company’s stock worth $183,000 after buying an additional 4,913 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in Supernus Pharmaceuticals during the third quarter worth about $262,000. Profund Advisors LLC grew its stake in Supernus Pharmaceuticals by 17.7% during the third quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 1,454 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Supernus Pharmaceuticals by 9.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,858 shares of the specialty pharmaceutical company’s stock valued at $314,000 after purchasing an additional 909 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $26.49 on Tuesday. The company’s 50 day moving average is $28.11 and its 200-day moving average is $29.28. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $35.44.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.